Burning Rock Biotech Ltd. ADR (BNR): Price and Financial Metrics
BNR Price/Volume Stats
Current price | $0.68 | 52-week high | $3.25 |
Prev. close | $0.68 | 52-week low | $0.57 |
Day low | $0.68 | Volume | 9,700 |
Day high | $0.71 | Avg. volume | 73,857 |
50-day MA | $0.85 | Dividend yield | N/A |
200-day MA | $1.24 | Market Cap | 70.07M |
BNR Stock Price Chart Interactive Chart >
Burning Rock Biotech Ltd. ADR (BNR) Company Bio
Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The company operates through following segment: central laboratory business, in-hospital business and pharma research and development services. Its products and clinical applications including companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. Burning Rock Biotech was founded by Yu Sheng Han in 2014 and is headquartered in Guangzhou, China.
Latest BNR News From Around the Web
Below are the latest news stories about BURNING ROCK BIOTECH LTD that investors may wish to consider to help them evaluate BNR as an investment opportunity.
Burning Rock Announces Results of 2023 Annual General MeetingGUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & You |
Burning Rock Biotech Limited (NASDAQ:BNR) Q3 2023 Earnings Call TranscriptBurning Rock Biotech Limited (NASDAQ:BNR) Q3 2023 Earnings Call Transcript November 30, 2023 Operator: Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation […] |
Q3 2023 Burning Rock Biotech Ltd Earnings CallQ3 2023 Burning Rock Biotech Ltd Earnings Call |
Burning Rock Reports Third Quarter 2023 Financial ResultsGUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advance |
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023GUANGZHOU, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 20, 2023 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, |
BNR Price Returns
1-mo | -16.31% |
3-mo | -9.33% |
6-mo | -27.27% |
1-year | -76.55% |
3-year | -97.22% |
5-year | N/A |
YTD | -26.88% |
2023 | -58.67% |
2022 | -76.39% |
2021 | -58.74% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...